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Abstract 
 
 
Objective: To assess the prognostic implications of the 6-minute walk test (6-MWT) 
distance measured twice, one year apart, in a large sample of patients with chronic 
heart failure (CHF) followed for an extended period (>8 years from baseline).  
Material and Methods: Patients undertook a 6-MWT at baseline and at one year, 
and were followed up for 8 years from baseline.  
Results:  600 patients (median [inter-quartile range, IQR]) (age 78 [72-84] years; 75% 
males; body mass index 27 [25-31] kg∙m-2; left ventricular ejection fraction 34 [26-38] 
%) were included. At baseline, median 6-MWT distance was 232 (60-386) m. There 
was no significant change in 6-MWT distance at one year (change -12m; P=0.533). 
During a median follow up of 8.0 years in survivors, 396 patients had died (66%). 
Four variables were independent predictors of all-cause mortality in a multivariable 
Cox model (adjusted for body mass index, age, QRS duration, left ventricular ejection 
fraction); increasing NT pro-BNP, decreasing 6-MWT distance at one year, decreasing 
haemoglobin, and increasing urea.  
Conclusions: Distance walked during the 6-MWT is an independent predictor of all-
cause mortality in patients with CHF. In survivors, the 6-MWT distance is stable at 
one year. The 6-MWT distance at one year carries similar prognostic information.  
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Introduction 
 
Cardiopulmonary exercise testing (CPET) is perhaps the “gold standard” method for 
assessing exercise capacity in patients with chronic heart failure (CHF), but it is not 
widely available. More simple tests of functional capacity are commonly used [9]. 
The distance walked during a six-minute walk test (6-MWT) is reproducible and 
sensitive to changes in quality of life [10, 12, 18]. It is a self-paced, sub-maximal test, 
and exercise intensity mimics activities of daily living in patients with mild-to-
moderate CHF [4, 2, 13]. The 6-MWT can be affected by a number of factors 
including: severity of heart failure, extent of co-morbidities [12], verbal 
encouragement provided by the healthcare professional [13], track layout, and the 
number of walk tests performed and their proximity to each other [4, 9].  
 
We have previously showed agreement between repeated 6-MWTs (12 months 
apart) in 74 patients with HF with unchanged symptoms (intra-class correlation 
coefficient =0.80; 95% CI = 0.69–0.87) [10]. However, in practice, symptoms and 
functional capacity may change over time. Studies suggest that 6-MWT distance 
increases with repeat testing [4]. This “learning effect” is likely to be affected by 
changes in symptoms and medication usage but also other factors such as patient 
motivation, familiarity with the test requirements, and psycho-social factors 
(including confidence and anxiety levels) [4, 8, 14].  
 The prognostic implication of 6-MWT distance from repeated tests is unclear. The 
aim of the present study was to assess the prognostic implications of 6-MWT 
distance measured twice, one year apart, in a large sample of patients with CHF 
followed for an extended period (>8 years from baseline).  
 
Methods 
The Hull and East Riding Ethics Committee approved the study, and all patients 
provided informed consent for participation. Clinical information obtained included 
past medical history and drug and smoking history. Clinical examination included 
assessment of body mass index (BMI), heart rate, rhythm, and blood pressure (BP). 
Heart failure was defined as current symptoms of heart failure, or a history of 
symptoms controlled by ongoing therapy, in the presence of reduced left ventricular 
(LV) systolic function on echocardiography and in the absence of any other cause for 
symptoms [18, 23]. 2D-echocardiography was carried out by one of three trained 
operators. LV function was assessed by estimation on a scale of normal, mild, mild-
to-moderate, moderate, moderate-to-severe, and severe impairment. LV ejection 
fraction (LVEF) was calculated using the Simpson’s formula, where possible, from 
measurements of end-diastolic and end-systolic volumes on apical 2D views, 
following the guidelines of Schiller and colleagues [23] and LVSD was diagnosed if 
LVEF was <45%.  
 
The 6-MWT was conducted following a standardised protocol [14]. A 15 m flat, 
obstacle-free corridor, with chairs placed at either end was used. Patients were 
instructed to walk as far as possible at a self-selected pace, turning 180° every 15 m 
in the allotted time of 6 min. Patients were able to rest, if needed, and the time 
remaining was called every second minute [4]. Patients were excluded if they were 
unable to walk without assistance from another person (not including mobility aids), 
or if they were unable to exercise because of non-cardiac limitations. Patients 
walked unaccompanied so as not to influence walking speed. After 6 min, patients 
were instructed to stop and the total distance covered was measured to the nearest 
metre. Standardised verbal encouragement was provided to patients at 2 min and 4 
min in a neutral tone. If a patient could not undertake the 6-MWT a distance of 0 m 
was recorded. The 6-MWT was repeated 12 months later.  
 
Statistical Analysis 
 
Continuous variables are presented as medians with inter-quartile ranges (IQR); 
categorical data as percentages. Continuous variables were assessed for normality by 
the Kolmogorov–Smirnov test. NT pro-BNP was normalised by log-transformation for 
analysis. No survivor was followed for fewer than 8 years from baseline. We used 
receiver operating characteristic (ROC) curves to assess the relation between 
variables at baseline and survival at 8 years from baseline, and report the area under 
the curve (AUC) with 95% confidence intervals (CI), sensitivity, specificity, and 
optimal cut-points. To define the optimal cut-point, we used the point closest to the 
upper left corner of the ROC curve, often known as the (0, 1) criterion.  
 
Cox regression models (univariable and multivariable) were used to develop 
predictor models using all baseline variables. We used multivariable Cox 
proportional hazards model using the backward likelihood ratio method (P value for 
entry was <0.05; P value for removal >0.1) to identify independent predictors of all-
cause mortality from candidate predictor variables. The assumption of 
proportionality was tested for each variable using the method of Grambsch and 
Therneau [7]. To minimise the risk of ‘overfitting’ we were guided by Peduzzi and 
colleagues [19, 26] who suggested an events per variable ratio of 10:1. To determine 
the robustness of our model(s) we performed bootstrapping based on 1,000 
stratified samples. SPSS version 19.0 (IBM, New York, USA) was used to analyse the 
data. An arbitrary level of 5% statistical significance was used throughout (two-
tailed). We followed the guidance of Perneger [20] and did not adjust for multiple 
testing in order to avoid the inflation of type I error. The primary outcome measure 
was all-cause mortality.  
 
Results 
600 patients (median [inter-quartile range, IQR]) (age 78 [72-84] years; 75% males; 
body mass index 27 [25-31]kg∙m-2; left ventricular ejection fraction 34 [26-38]%) with 
heart failure due to left ventricular systolic impairment were included in the study 
(Table 1). At baseline, median 6-MWT distance was 232 (60-386) m, and quartile 
ranges for 6-MWT distance were <60m, 61-270m, 271-365m, and >365m. After a 
median follow up of 374 (21-45) days the 6-MWT was repeated and walking distance 
was unchanged (change -12m; P=0.533). Figure 1 shows limits of agreement for 
difference in walking distance between baseline and one year (y=-0.0784x + 27.663;     
R2=0.0068; P=0.657). During a median follow up of 8.0 years in survivors, 396 
patients had died (66%). 
 Ten variables were significantly associated with all-cause mortality following the one 
year test in univariable Cox analysis (Table 2) including baseline 6-MWT distance (χ2 = 
61.1; P<0.0001) and one year 6-MWT distance (χ2 = 59.5; P<0.0001). After 
bootstrapping, 11 variables remained statistically significant (Table 3) including 
baseline 6-MWT and 1-year 6-MWT distance.  
 
All variables in Table 2 were included in a final multivariable Cox model, and four 
were independent predictors of all-cause mortality when adjusted for body mass 
index, age, QRS duration, and left ventricular ejection fraction; increasing NT pro-
BNP, decreasing 6-MWT distance at one year, decreasing haemoglobin, and 
increasing urea (Table 4). We re-ran the multivariable model by forcing baseline 6-
MWT distance into it instead of 6-MWT distance at one year; we noted that the 
overall Chi-square value for the model remained unchanged. 
 
Receiver operating characteristic curve analysis of the relation between the two 6-
MWT distances and all-cause mortality at 8 years from baseline is shown in Figure 2. 
For baseline distance, AUC= 0.67; P<0.0001; 95% CI = 0.63–0.71; the optimal cut-
point for baseline 6-MWT distance was 325m with sensitivity 0.75 and specificity 
0.54); and for one year distance AUC= 0.66; P<0.0001; 95% CI = 0.62–0.70; sensitivity 
0.73; specificity 0.53; optimal cut-point 327m). 
 
Discussion 
We have shown that distance walked during a 6-MWT both at baseline and at one 
year is an independent predictor of subsequent all-cause mortality in patients with 
CHF. The 6-MWT distance at one year carries similar prognostic information to 
baseline values. We believe ours is the first study which has considered the 
prognostic implications of 6-MWT distance measured twice, one year apart in 
patients with CHF. We have shown that in survivors, the 6-MWT distance is stable at 
one year. There is thus little to be gained from repeating the 6-MWT at one year in 
clinical practice. 
 
We have previously shown that 6-MWT distance is an independent predictor of all-
cause mortality. In 1 592 patients, 212 died representing a crude death rate of 
13.3%. Five independent predictors of all-cause mortality were identified including 
decreasing 6-MWT distance [14]. Few studies have reported serial follow up of 6-
MWT distance in cardiac patients. Cheetham and colleagues [6] conducted repeated 
6-MWTs at baseline, 6 weeks, 12 weeks, and 18 weeks in patients awaiting heart 
transplantation (all patients had a history of at least 6 months of symptomatic heart 
failure). Distance walked ranged from 457 ± 28m to 470± 30m across the four time 
points (greatest distance being at the second time point). Although the mean 
distance at each time-point was greater than in our study, the mean change of 13m 
over 18 weeks was similar to our findings (-12m), albeit over 52 weeks. Cheetham 
and co-workers [6] did not perform a survival analysis but they concluded that the 6-
MWT had limited utility in terms of repeated assessment of clinical status in patients 
with advanced heart failure. 
 
Alison and colleagues [2] conducted repeated 6-MWTs after 6 months in 173 
patients with significant pulmonary disease, and reported a mean increase of 119 m 
compared to baseline. Our follow up period was longer (1 year) and it is possible that 
any learning effect is lost over this period as other factors such as increasing age and 
severity of disease may become more significant drivers of walking performance.  
 
The reproducibility of repeated 6-MWTs has been questioned due to inconsistencies 
in testing protocol. There is little agreement regarding the length or shape of the test 
course, whether a practice walk should be conducted, and which test result should 
be reported (i.e. first test, final test, best test, mean test score). Each of these issues 
is of particular importance when comparing serial data from multicentre trials. A 7 to 
14% improvement in the second 6-MWT has been reported in patients with COPD 
[21, 24]. Sciurba and co-workers [24] reported that 761 patients with severe 
emphysema walked further (363m) during a second 6-MWT than during a first test 
one day before (343m). They argued that this was due to patients becoming familiar 
with the walking course, more motivated or using better pacing strategies. Similar 
short term improvement in 6-MWT distance has also been reported in older, 
apparently healthy individuals [27], and patients with heart failure [21].  
 
Adsett and co-workers [1] investigated whether repeated performance of 6-MWTs 
was related to the time interval between tests or the baseline performance in 88 
patients with stable CHF. The authors reported a mean difference of 12 metres 
between the first and second tests and concluded that this would be clinically 
insignificant. Patients with a poor baseline 6-MWT distance showed no learning 
effect, and Adsett et al [1] concluded that repeated testing was unnecessary in their 
cohort of patients with CHF.   
 
The optimum cut-point in our study was 325m, patients walking less than this 
distance were at an increased risk of all-cause mortality. Our findings our similar to a 
previous study which reported a cut off <300m for predicting increased likelihood of 
death or pre-transplant hospital admission in 45 patients with more advanced heart 
failure [5] than those recruited to our study.  
 
Study Limitations  
We acknowledge that a number of confounding variables may affect performance in 
repeated 6-MWT over a period of 12 months including changes in lifestyle, 
medication usage, deterioration or improvement in symptom severity, or surgical 
intervention. The American Thoracic Society [3] recommended that corridor distance 
should be 30m. Our corridor was 15m meaning that patients must turn more 
frequently during the 6-minute period. Therefore, the distance “norms” we report 
are likely to underestimate walking performance in this cohort of patients. The 6-
MWT is not a test of maximal exercise capacity but is a test of submaximal exercise 
performance [13]. The American Thoracic Society [3] advocates that verbal 
encouragement should be limited, and tone of voice be controlled during the 6-MWT 
in an elderly, chronic disease population. We have followed this approach with our 
patients but different centres will operate different systems. Therefore, findings 
from our current study should not be extrapolated to other populations, or to other 
research centres that may use a more aggressive 6-MWT coaching style.  
Furthermore, patients who had a poorer 6-MWT distance may preferentially have 
died before the second measurement. The effect is to dilute the relation between 
baseline 6-MWT and outcome. 
 
Conclusion: In survivors, the 6-MWT distance is stable at one year. Distance walked 
during the 6-MWT is an independent predictor of all-cause mortality in patients with 
CHF. The relation is similar when the test is repeated at one year, suggesting that 
there is limited clinical utility in repeating the 6-MWT.  
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